Shanghai Kaibao Pharmaceutical Net Assets

Latest as of June 2026: CN¥4.29 Billion CNY ≈ $627.03 Million USD

Shanghai Kaibao Pharmaceutical net assets. Based on the latest financial reports, Shanghai Kaibao Pharmaceutical (300039) has net assets worth CN¥4.29 Billion CNY (≈ $627.03 Million USD) as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥4.59 Billion ≈ $672.24 Million USD) and total liabilities (CN¥308.94 Million ≈ $45.21 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore 300039 year-over-year net asset growth to track the company's year-over-year net asset growth rate.

Key Net Assets Metrics

Metric	Value
Current Net Assets	CN¥4.29 Billion
% of Total Assets	93.28%
Annual Growth Rate	28.58%
5-Year Change	45.12%
10-Year Change	100.82%
Growth Volatility	177.19

Net Assets of Shanghai Kaibao Pharmaceutical (2006–2025)

Net assets of Shanghai Kaibao Pharmaceutical from 2006 to 2025. This chart illustrates how Shanghai Kaibao Pharmaceutical's net assets have evolved over time, based on quarterly financial data. See Shanghai Kaibao Pharmaceutical balance sheet quality to measure how much of total assets are equity-financed.

Annual Net Assets for Shanghai Kaibao Pharmaceutical (2006–2025)

The table below shows the annual net assets of Shanghai Kaibao Pharmaceutical from 2006 to 2025. For live market cap and overall valuation, see Shanghai Kaibao Pharmaceutical stock valuation.

Year	Net Assets	Change
2025-12-31	CN¥4.42 Billion ≈ $646.60 Million	+7.69%
2024-12-31	CN¥4.10 Billion ≈ $600.40 Million	+1.74%
2023-12-31	CN¥4.03 Billion ≈ $590.13 Million	+7.23%
2022-12-31	CN¥3.76 Billion ≈ $550.36 Million	+23.52%
2021-12-31	CN¥3.04 Billion ≈ $445.57 Million	+18.10%
2020-12-31	CN¥2.58 Billion ≈ $377.29 Million	+0.34%
2019-12-31	CN¥2.57 Billion ≈ $376.00 Million	+3.39%
2018-12-31	CN¥2.49 Billion ≈ $363.65 Million	+5.06%
2017-12-31	CN¥2.37 Billion ≈ $346.14 Million	+7.51%
2016-12-31	CN¥2.20 Billion ≈ $321.97 Million	+9.71%
2015-12-31	CN¥2.01 Billion ≈ $293.47 Million	+6.41%
2014-12-31	CN¥1.88 Billion ≈ $275.78 Million	+17.34%
2013-12-31	CN¥1.61 Billion ≈ $235.02 Million	+13.20%
2012-12-31	CN¥1.42 Billion ≈ $207.61 Million	+6.32%
2011-12-31	CN¥1.33 Billion ≈ $195.27 Million	+7.88%
2010-12-31	CN¥1.24 Billion ≈ $181.01 Million	+7.92%
2009-12-31	CN¥1.15 Billion ≈ $167.72 Million	+803.05%
2008-12-31	CN¥126.92 Million ≈ $18.57 Million	+64.92%
2007-12-31	CN¥76.96 Million ≈ $11.26 Million	+106.69%
2006-12-31	CN¥37.24 Million ≈ $5.45 Million	--

Equity Component Analysis

This analysis shows how different components contribute to Shanghai Kaibao Pharmaceutical's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have grown by 10145.9% over the analyzed period, indicating profitable operations and earnings retention.

Shanghai Kaibao Pharmaceutical Net Assets Breakdown (December 2025)

Shanghai Kaibao Pharmaceutical net assets breakdown by equity component as of December 2025.

Component	Amount	Percentage
Retained Earnings	CN¥2.22 Billion	50.33%
Other Components	CN¥2.19 Billion	49.67%
Total Equity	CN¥4.42 Billion	100.00%

Shanghai Kaibao Pharmaceutical Competitors by Market Cap

The table below lists competitors of Shanghai Kaibao Pharmaceutical ranked by their market capitalization.

Company	Market Cap
Judo Capital Holdings Ltd AU:JDO	$737.84 Million
Changchun Engley Automobile Industry Co.Ltd. SHG:601279	$737.92 Million
Nanjing Kangni Mechanical & Electrical Co Ltd SHG:603111	$737.93 Million
Tipco Asphalt Public Company Limited BK:TASCO-R	$737.94 Million
SK Securities Co Ltd Preference Shares KO:001515	$737.75 Million
Da-Cin Construction Co Ltd TW:2535	$737.74 Million
Cicor Technologies Ltd SW:CICN	$737.72 Million
Infund Holding Co Ltd SHE:002141	$737.62 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Shanghai Kaibao Pharmaceutical's equity between the two most recent reporting periods.

Equity Growth Insights

From 2024 to 2025, total equity changed from 4,102,051,563 to 4,418,331,904, a change of 316,280,341 (7.7%).
Net income of 278,584,265 contributed positively to equity growth.
Dividend payments of 136,032,189 reduced retained earnings.
Other comprehensive income decreased equity by 1,021,741,514.
Other factors increased equity by 1,195,469,779.

Equity Change Factors (2024 to 2025)

Factor	Impact	Contribution
Net Income	CN¥278.58 Million	+6.31%
Dividends Paid	CN¥136.03 Million	-3.08%
Other Comprehensive Income	CN¥-1.02 Billion	-23.13%
Other Changes	CN¥1.20 Billion	+27.06%
Total Change	CN¥-	7.71%

Book Value vs Market Value Analysis

This analysis compares Shanghai Kaibao Pharmaceutical's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 1.14x
The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
The price-to-book ratio has decreased from 15.11x to 1.14x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2006-12-31	CN¥0.32	CN¥4.82	x
2007-12-31	CN¥0.64	CN¥4.82	x
2008-12-31	CN¥0.16	CN¥4.82	x
2009-12-31	CN¥1.43	CN¥4.82	x
2010-12-31	CN¥1.16	CN¥4.82	x
2011-12-31	CN¥1.26	CN¥4.82	x
2012-12-31	CN¥1.33	CN¥4.82	x
2013-12-31	CN¥1.50	CN¥4.82	x
2014-12-31	CN¥1.76	CN¥4.82	x
2015-12-31	CN¥1.85	CN¥4.82	x
2016-12-31	CN¥2.05	CN¥4.82	x
2017-12-31	CN¥2.17	CN¥4.82	x
2018-12-31	CN¥2.35	CN¥4.82	x
2019-12-31	CN¥2.43	CN¥4.82	x
2020-12-31	CN¥2.47	CN¥4.82	x
2021-12-31	CN¥2.91	CN¥4.82	x
2022-12-31	CN¥3.60	CN¥4.82	x
2023-12-31	CN¥3.85	CN¥4.82	x
2024-12-31	CN¥3.92	CN¥4.82	x
2025-12-31	CN¥4.22	CN¥4.82	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Shanghai Kaibao Pharmaceutical utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): 6.31%
The company has moderate efficiency in generating returns from equity.
DuPont Analysis Breakdown:
• Net Profit Margin: 24.17%
• Asset Turnover: 0.24x
• Equity Multiplier: 1.08x
Recent ROE (6.31%) is below the historical average (17.00%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2006	56.04%	12.54%	1.53x	2.93x	CN¥17.14 Million
2007	59.68%	17.36%	1.60x	2.15x	CN¥37.30 Million
2008	45.42%	14.88%	1.69x	1.81x	CN¥44.96 Million
2009	5.99%	14.96%	0.34x	1.17x	CN¥-45.95 Million
2010	10.00%	20.50%	0.44x	1.11x	CN¥-1.02K
2011	12.56%	20.44%	0.56x	1.09x	CN¥34.12 Million
2012	17.07%	22.22%	0.70x	1.10x	CN¥100.31 Million
2013	19.85%	24.09%	0.75x	1.10x	CN¥158.21 Million
2014	18.67%	21.71%	0.77x	1.12x	CN¥163.46 Million
2015	14.04%	20.18%	0.58x	1.21x	CN¥81.10 Million
2016	12.84%	18.88%	0.59x	1.15x	CN¥62.58 Million
2017	11.51%	17.35%	0.59x	1.13x	CN¥35.76 Million
2018	9.13%	15.11%	0.55x	1.11x	CN¥-21.70 Million
2019	9.77%	17.69%	0.50x	1.11x	CN¥-5.96 Million
2020	4.12%	11.69%	0.32x	1.12x	CN¥-151.71 Million
2021	4.60%	12.73%	0.33x	1.10x	CN¥-164.38 Million
2022	5.07%	17.05%	0.26x	1.13x	CN¥-185.37 Million
2023	8.13%	20.57%	0.35x	1.14x	CN¥-75.25 Million
2024	9.16%	25.49%	0.33x	1.10x	CN¥-34.63 Million
2025	6.31%	24.17%	0.24x	1.08x	CN¥-163.25 Million

Industry Comparison

This section compares Shanghai Kaibao Pharmaceutical's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

Industry: Drug Manufacturers - Specialty & Generic
Average net assets among peers: $3,632,405,673
Average return on equity (ROE) among peers: 7.53%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Shanghai Kaibao Pharmaceutical (300039)	CN¥4.29 Billion	56.04%	0.07x	$737.76 Million
Shenzhen Neptunus Bioengineering Co Ltd (000078)	$1.97 Billion	4.04%	0.54x	$488.97 Million
Anhui Fengyuan Pharmaceutical Co Ltd (000153)	$560.87 Million	4.60%	0.22x	$360.39 Million
Shan Dong Dong-E E-Jiao Co Ltd (000423)	$1.02 Billion	12.46%	0.13x	$4.73 Billion
Livzon Pharmaceutical Group Inc (000513)	$1.04 Billion	4.29%	0.46x	$2.58 Billion
Wedge Industrial Co Ltd (000534)	$0.00	0.00%	0.00x	$1.20 Billion
Yunnan Baiyao Group Co Ltd (000538)	$18.14 Billion	17.33%	0.53x	$14.52 Billion
Hainan Haiyao Co Ltd (000566)	$491.82 Million	6.71%	1.19x	$755.58 Million
Tus Pharmaceutical Group Co Ltd (000590)	$280.91 Million	1.46%	1.58x	$272.98 Million
Northeast Pharmaceutical Group Co Ltd (000597)	$5.57 Billion	7.36%	1.59x	$920.83 Million
Jilin Aodong Pharmaceutical Group Co Ltd (000623)	$7.25 Billion	17.08%	0.09x	$3.02 Billion

About Shanghai Kaibao Pharmaceutical

SHE:300039 China Drug Manufacturers - Specialty & Generic

Market Cap

$737.76 Million

CN¥5.04 Billion CNY

Market Cap Rank

#9922 Global

#2525 in China

Share Price

CN¥4.82

Change (1 day)

+0.63%

52-Week Range

CN¥4.18 - CN¥6.66

All Time High

CN¥12.44